

DAFTAR PUSTAKA

- Ahmadi, M., Mahmoodi, M., Shoaran, M., Nazari-Khanamiri, F., & Rezaie, J. (2022). Harnessing Normal and Engineered Mesenchymal Stem Cells Derived Exosomes for Cancer Therapy: Opportunity and Challenges. *International journal of molecular sciences*, 23(22), 13974. <https://www.mdpi.com/1422-0067/23/22/13974>
- Almansour, N. M. (2022). Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. *Frontiers in Molecular Biosciences*, 9, 836417.
- Amiri, A., Bagherifar, R., Ansari Dezfouli, E., Kiaie, S. H., Jafari, R., & Ramezani, R. (2022). Exosomes as bio-inspired nanocarriers for RNA delivery: Preparation and applications. *Journal of translational medicine*, 20(1), 1-16.
- Anders, C. K., Abramson, V., Tan, T., & Dent, R. (2016). The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. *American Society of Clinical Oncology Educational Book*(36), 34-42. https://doi.org/10.1200/edbk_159135
- Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020). microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis [Review]. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.581007>
- Armstrong, L., Willoughby, C. E., & McKenna, D. J. (2023). Targeting of AKT1 by miR-143-3p Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer. *Cells*, 12(18), 2207. <https://www.mdpi.com/2073-4409/12/18/2207>
- Asghariazar, V., Kadkhodayi, M., Sarailoo, M., Jolfayi, A. G., & Baradaran, B. (2023). MicroRNA-143 as a potential tumor suppressor in cancer: An insight into molecular targets and signaling pathways. *Pathology - Research and Practice*, 250, 154792. <https://doi.org/https://doi.org/10.1016/j.prp.2023.154792>
- Atienza, J. M., Roth, R. B., Rosette, C., Smylie, K. J., Kammerer, S., Rehbock, J., Ekblom, J., & Denissenko, M. F. (2005). Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. *Mol Cancer Ther*, 4(3), 361-368. <https://doi.org/10.1158/1535-7163.Mct-04-0241>
- Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*, 116(2), 281-297. [https://doi.org/10.1016/s0092-8674\(04\)00045-5](https://doi.org/10.1016/s0092-8674(04)00045-5)
- Buhagiari, A., Seria, E., Borg, M., Borg, J., & Ayers, D. (2021). Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type

- profiling and chemoresistance. *Cancer Drug Resist*, 4(4), 934-945. <https://doi.org/10.20517/cdr.2021.62>
- Cen, Y., Xu, L., Huang, S., & Zhuang, S. (2019). miR-143-3p functions as a tumor suppressor by targeting HK2 in neuroblastomas. *Int J Clin Exp Med*, 12(7), 8450-8460.
- Chavez, K. J., Garimella, S. V., & Lipkowitz, S. (2010). Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. *Breast Dis*, 32(1-2), 35-48. <https://doi.org/10.3233/bd-2010-0307>
- Chen, F., Kang, R., Liu, J., & Tang, D. (2022). The V-ATPases in cancer and cell death. *Cancer Gene Therapy*, 29(11), 1529-1541. <https://doi.org/10.1038/s41417-022-00477-y>
- Chen, H., Wang, L., Zeng, X., Schwarz, H., Nanda, H. S., Peng, X., & Zhou, Y. (2021a). Exosomes, a new star for targeted delivery. *Frontiers in Cell and Developmental Biology*, 9, 751079.
- Chen, H., Wang, L., Zeng, X., Schwarz, H., Nanda, H. S., Peng, X., & Zhou, Y. (2021b). Exosomes, a New Star for Targeted Delivery [Review]. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.751079>
- Chen, J., Li, P., Zhang, T., Xu, Z., Huang, X., Wang, R., & Du, L. (2022). Review on Strategies and Technologies for Exosome Isolation and Purification [Review]. *Frontiers in Bioengineering and Biotechnology*, 9. <https://doi.org/10.3389/fbioe.2021.811971>
- Chi, W., Xiu, B., Xiong, M., Wang, X., Li, P., Zhang, Q., Hou, J., Sang, Y., Zhou, X., Chen, M., Zheng, S., Zhang, L., Xue, J., Chi, Y., & Wu, J. (2024). MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer. *International journal of molecular sciences*, 25(1), 221. <https://www.mdpi.com/1422-0067/25/1/221>
- Choi, Y. L., Bocanegra, M., Kwon, M. J., Shin, Y. K., Nam, S. J., Yang, J. H., Kao, J., Godwin, A. K., & Pollack, J. R. (2010). LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. *Cancer Res*, 70(6), 2296-2306. <https://doi.org/10.1158/0008-5472.Can-09-3141>
- Christowitz, C., Davis, T., Isaacs, A., Van Niekerk, G., Hattingh, S., & Engelbrecht, A.-M. (2019). Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. *BMC cancer*, 19(1), 1-10.

- Comfort, N., Cai, K., Bloomquist, T. R., Strait, M. D., Ferrante, A. W., Jr., & Baccarelli, A. A. (2021). Nanoparticle Tracking Analysis for the Quantification and Size Determination of Extracellular Vesicles. *J Vis Exp*(169). <https://doi.org/10.3791/62447>
- Crouch, B., Murphy, H., Belonwu, S., Martinez, A., Gallagher, J., Hall, A., Soo, M. S., Lee, M., Hughes, P., Haystead, T., & Ramanujam, N. (2017). Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. *Sci Rep*, 7(1), 17487. <https://doi.org/10.1038/s41598-017-17832-x>
- Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020). Exosomes: key players in cancer and potential therapeutic strategy. *Signal Transduction and Targeted Therapy*, 5(1), 145. <https://doi.org/10.1038/s41392-020-00261-0>
- Dai, X., Cheng, H., Bai, Z., & Li, J. (2017). Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. *J Cancer*, 8(16), 3131-3141. <https://doi.org/10.7150/jca.18457>
- Dang, M. N., Gomez Casas, C., & Day, E. S. (2021). Photoresponsive miR-34a/Nanoshell Conjugates Enable Light-Triggered Gene Regulation to Impair the Function of Triple-Negative Breast Cancer Cells. *Nano Lett*, 21(1), 68-76. <https://doi.org/10.1021/acs.nanolett.0c03152>
- Dasgupta, T., Antony, J., Braithwaite, A. W., & Horsfield, J. A. (2016). HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells. *J Biol Chem*, 291(24), 12761-12770. <https://doi.org/10.1074/jbc.M115.704627>
- Dass, S. A., Tan, K. L., Selva Rajan, R., Mokhtar, N. F., Mohd Adzmi, E. R., Wan Abdul Rahman, W. F., Tengku Din, T., & Balakrishnan, V. (2021). Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. *Medicina (Kaunas)*, 57(1). <https://doi.org/10.3390/medicina57010062>
- de Abreu, R. C., Ramos, C. V., Becher, C., Lino, M., Jesus, C., da Costa Martins, P. A., Martins, P. A. T., Moreno, M. J., Fernandes, H., & Ferreira, L. (2021). Exogenous loading of miRNAs into small extracellular vesicles. *J Extracell Vesicles*, 10(10), e12111. <https://doi.org/10.1002/jev2.12111>
- Du, Y., Zhang, J., Meng, Y., Huang, M., Yan, W., & Wu, Z. (2020). MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells. *AMB Express*, 10(1), 134. <https://doi.org/10.1186/s13568-020-01072-w>

- Duan, Z. Y., Cai, G. Y., Li, J. J., Bu, R., Wang, N., Yin, P., & Chen, X. M. (2018). U6 can be used as a housekeeping gene for urinary sediment miRNA studies of IgA nephropathy. *Sci Rep*, 8(1), 10875. <https://doi.org/10.1038/s41598-018-29297-7>
- Esses, K. M., Hagmaier, R. M., Blanchard, S. A., Lazarchick, J. J., & Riker, A. I. (2009). Carcinosarcoma of the breast: two case reports and review of the literature. *Cases J*, 2(1), 15. <https://doi.org/10.1186/1757-1626-2-15>
- Fa, X., Song, P., Fu, Y., Deng, Y., & Liu, K. (2021). Long non-coding RNA VPS9D1-AS1 facilitates cell proliferation, migration and stemness in hepatocellular carcinoma. *Cancer cell international*, 21(1), 131. <https://doi.org/10.1186/s12935-020-01741-7>
- Fan, T., Sun, N., & He, J. (2020). Exosome-Derived LncRNAs in Lung Cancer. *Front Oncol*, 10, 1728. <https://doi.org/10.3389/fonc.2020.01728>
- Frixa, T., Donzelli, S., & Blandino, G. (2015). Oncogenic MicroRNAs: Key Players in Malignant Transformation. *Cancers (Basel)*, 7(4), 2466-2485. <https://doi.org/10.3390/cancers7040904>
- Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021). MicroRNA as an Important Target for Anticancer Drug Development [Review]. *Frontiers in Pharmacology*, 12. <https://doi.org/10.3389/fphar.2021.736323>
- Gan, Y., Ye, F., & He, X. X. (2020). The role of YWHAZ in cancer: A maze of opportunities and challenges. *J Cancer*, 11(8), 2252-2264. <https://doi.org/10.7150/jca.41316>
- Garlapati, C., Joshi, S., Bhattarai, S., Krishnamurthy, J., Turaga, R. C., Nguyen, T., Li, X., & Aneja, R. (2023). PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. *Cell Death & Disease*, 14(1), 12. <https://doi.org/10.1038/s41419-022-05539-5>
- Garreau, M., Weidner, J., Hamilton, R., Kolosionek, E., Toki, N., Stavenhagen, K., Paris, C., Bonetti, A., Czechtizky, W., Gnerlich, F., & Rydzik, A. (2024). Chemical modification patterns for microRNA therapeutic mimics: a structure-activity relationship (SAR) case-study on miR-200c. *Nucleic acids research*, 52(6), 2792-2807. <https://doi.org/10.1093/nar/gkae141>
- Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. *Cancer discovery*, 9(2), 176-198.

- Ghafouri-Fard, S., Shoorei, H., Nofaresti, L., Hussen, B. M., Moghadam, M. H. B., Taheri, M., & Rashnoo, F. (2023). Nanoparticle-mediated delivery of microRNAs-based therapies for treatment of disorders. *Pathology - Research and Practice*, 248, 154667. <https://doi.org/https://doi.org/10.1016/j.prp.2023.154667>
- Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. *Bioorganic chemistry*, 88, 102925.
- Gurung, S., Perocheau, D., Touramanidou, L., & Baruteau, J. (2021). The exosome journey: from biogenesis to uptake and intracellular signalling. *Cell Commun Signal*, 19(1), 47. <https://doi.org/10.1186/s12964-021-00730-1>
- Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. *Nature Reviews Molecular Cell Biology*, 15(8), 509-524. <https://doi.org/10.1038/nrm3838>
- Hackett, A. J., Smith, H. S., Springer, E. L., Owens, R. B., Nelson-Rees, W. A., Riggs, J. L., & Gardner, M. B. (1977). Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. *Journal of the National Cancer Institute*, 58(6), 1795-1806.
- Haryana, S. M. (2016). Long Non-Coding RNA (lncRNA) and MicroRNA (miRNA) in Cancer Management. *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 48(4).
- Hmadcha, A., Martin-Montalvo, A., Gauthier, B. R., Soria, B., & Capilla-Gonzalez, V. (2020). Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy [Review]. *Frontiers in Bioengineering and Biotechnology*, 8. <https://doi.org/10.3389/fbioe.2020.00043>
- Hou, Y., Feng, H., Jiao, J., Qian, L., Sun, B., Chen, P., Li, Q., & Liang, Z. (2019). Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7. *Artificial Cells, Nanomedicine, and Biotechnology*, 47(1), 2065-2071. <https://doi.org/10.1080/21691401.2019.1620252>
- Issac, M. S. M., Yousef, E., Tahir, M. R., & Gaboury, L. A. (2019). MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. *Neoplasia*, 21(10), 1015-1035. <https://doi.org/10.1016/j.neo.2019.07.011>
- Jiang, W., Wang, X., Zhang, C., Xue, L., & Yang, L. (2020). Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. *Oncol Lett*, 19(3), 1842-1848. <https://doi.org/10.3892/ol.2020.11274>

- Jonkman, J. E., Cathcart, J. A., Xu, F., Bartolini, M. E., Amon, J. E., Stevens, K. M., & Colarusso, P. (2014). An introduction to the wound healing assay using live-cell microscopy. *Cell Adh Migr*, 8(5), 440-451. <https://doi.org/10.4161/cam.36224>
- Kang, J. Y., Park, H., Kim, H., Mun, D., Park, H., Yun, N., & Joung, B. (2019). Human peripheral blood-derived exosomes for microRNA delivery. *Int J Mol Med*, 43(6), 2319-2328. <https://doi.org/10.3892/ijmm.2019.4150>
- Kar, R., Dhar, R., Mukherjee, S., Nag, S., Gorai, S., Mukerjee, N., Mukherjee, D., Vatsa, R., Chandrakanth Jadhav, M., & Ghosh, A. (2023). Exosome-based smart drug delivery tool for cancer theranostics. *ACS biomaterials science & engineering*, 9(2), 577-594.
- Kauanova, S., Urazbayev, A., & Vorobjev, I. (2021). The Frequent Sampling of Wound Scratch Assay Reveals the “Opportunity” Window for Quantitative Evaluation of Cell Motility-Impeding Drugs [Original Research]. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.640972>
- Kaurani, L. (2024). Clinical Insights into MicroRNAs in Depression: Bridging Molecular Discoveries and Therapeutic Potential. *International journal of molecular sciences*, 25(5), 2866. <https://www.mdpi.com/1422-0067/25/5/2866>
- Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., Gray, J. W., & Bissell, M. J. (2007). The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. *Molecular oncology*, 1(1), 84-96. <https://doi.org/https://doi.org/10.1016/j.molonc.2007.02.004>
- Kim, G. B., Shon, O.-J., Seo, M.-S., Choi, Y., Park, W. T., & Lee, G. W. (2021). Mesenchymal Stem Cell-Derived Exosomes and Their Therapeutic Potential for Osteoarthritis. *Biology*, 10(4), 285. <https://www.mdpi.com/2079-7737/10/4/285>
- Kuriyama, N., Yoshioka, Y., Kikuchi, S., Okamura, A., Azuma, N., & Ochiya, T. (2021). Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines. *Cancers (Basel)*, 13(23). <https://doi.org/10.3390/cancers13236137>
- Kurozumi, S., Yamaguchi, Y., Kurozumi, M., Ohira, M., Matsumoto, H., & Horiguchi, J. (2017). Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. *Journal of human genetics*, 62(1), 15-24.

- Lang, L., Tao, J., Yang, C., & Li, W. (2022). Tumor suppressive role of microRNA-4731-5p in breast cancer through reduction of PAICS-induced FAK phosphorylation. *Cell Death Discovery*, 8(1), 154. <https://doi.org/10.1038/s41420-022-00938-1>
- Le, M. N., & Nguyen, T. A. (2023). Innovative microRNA quantification by qPCR. *Mol Ther Nucleic Acids*, 31, 628-630. <https://doi.org/10.1016/j.omtn.2023.02.012>
- Lee, C., Fernandez, K. J., Alexandrou, S., Sergio, C. M., Deng, N., Rogers, S., Burgess, A., & Caldon, C. E. (2020). Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer. *Cancers (Basel)*, 12(8). <https://doi.org/10.3390/cancers12082268>
- Lee, S. H., & Jun, B.-H. (2019). Silver nanoparticles: synthesis and application for nanomedicine. *International journal of molecular sciences*, 20(4), 865.
- Leon-Ferre, R. A., & Goetz, M. P. (2023). Advances in systemic therapies for triple negative breast cancer. *Bmj*, 381, e071674. <https://doi.org/10.1136/bmj-2022-071674>
- Li, D., Hu, J., Song, H., Xu, H., Wu, C., Zhao, B., Xie, D., Wu, T., Zhao, J., & Fang, L. (2017). miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. *Am J Transl Res*, 9(5), 2276-2285.
- Li, Y., Meng, L., Li, B., Li, Y., Shen, T., & Zhao, B. (2022). The Exosome Journey: From Biogenesis to Regulation and Function in Cancers. *J Oncol*, 2022, 9356807. <https://doi.org/10.1155/2022/9356807>
- Li, Y., Wang, S., Zhang, X., Yang, R., Wei, X., Yan, R., Jiang, Y., & Shen, W. (2021). Expression Characteristics and Significant Prognostic Values of PGK1 in Breast Cancer. *Front Mol Biosci*, 8, 695420. <https://doi.org/10.3389/fmolb.2021.695420>
- Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022). Recent advances in therapeutic strategies for triple-negative breast cancer. *Journal of hematology & oncology*, 15(1), 121. <https://doi.org/10.1186/s13045-022-01341-0>
- Liang, W., Han, B., Hai, Y., Sun, D., & Yin, P. (2021). Mechanism of Action of Mesenchymal Stem Cell-Derived Exosomes in the Intervertebral Disc Degeneration Treatment and Bone Repair and Regeneration. *Front Cell Dev Biol*, 9, 833840. <https://doi.org/10.3389/fcell.2021.833840>

- Lobel, J. H., Tibble, R. W., & Gross, J. D. (2019). Pat1 activates late steps in mRNA decay by multiple mechanisms. *Proceedings of the National Academy of Sciences*, *116*(47), 23512-23517. <https://doi.org/doi:10.1073/pnas.1905455116>
- Łukaszewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers (Basel)*, *13*(17). <https://doi.org/10.3390/cancers13174287>
- Ma, Z. J., Yang, J. J., Lu, Y. B., Liu, Z. Y., & Wang, X. X. (2020). Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine. *World J Stem Cells*, *12*(8), 814-840. <https://doi.org/10.4252/wjsc.v12.i8.814>
- Manjunath, M., & Choudhary, B. (2021). Triple-negative breast cancer: A run-through of features, classification and current therapies. *Oncology Letters*, *22*(1), 1-21.
- Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009). A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biology*, *10*(6), R64. <https://doi.org/10.1186/gb-2009-10-6-r64>
- Mir, M. A., & Haq, B. U. (2023). CDK1 dysregulation in breast cancer. In *Therapeutic potential of cell cycle kinases in breast cancer* (pp. 195-210). Springer.
- Moon, B., & Chang, S. (2022). Exosome as a Delivery Vehicle for Cancer Therapy. *Cells*, *11*(3). <https://doi.org/10.3390/cells11030316>
- Ng, E. K., Li, R., Shin, V. Y., Siu, J. M., Ma, E. S., & Kwong, A. (2014). MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. *Tumour Biol*, *35*(3), 2591-2598. <https://doi.org/10.1007/s13277-013-1341-7>
- O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in endocrinology*, *9*, 402.
- O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol (Lausanne)*, *9*, 402. <https://doi.org/10.3389/fendo.2018.00402>
- O'Toole, S. A., Beith, J. M., Millar, E. K. A., West, R., McLean, A., Cazet, A., Swarbrick, A., & Oakes, S. R. (2013). Therapeutic targets in triple negative breast cancer. *Journal of Clinical Pathology*, *66*(6), 530-542. <https://doi.org/10.1136/jclinpath-2012-201361>

- Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. *Pharmaceutics*, *15*(7), 1796. <https://www.mdpi.com/1999-4923/15/7/1796>
- Otmani, K., & Lewalle, P. (2021). Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications [Review]. *Frontiers in Oncology*, *11*. <https://doi.org/10.3389/fonc.2021.708765>
- Pagliuca, A., Valvo, C., Fabrizi, E., Di Martino, S., Biffoni, M., Runci, D., Forte, S., De Maria, R., & Ricci-Vitiani, L. (2013). Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. *Oncogene*, *32*(40), 4806-4813.
- Peng, F., Xiong, L., Tang, H., Peng, C., & Chen, J. (2016). Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer. *Tumor Biology*, *37*, 14463-14477.
- Piasecka, D., Braun, M., Kordek, R., Sadej, R., & Romanska, H. (2018). MicroRNAs in regulation of triple-negative breast cancer progression. *J Cancer Res Clin Oncol*, *144*(8), 1401-1411. <https://doi.org/10.1007/s00432-018-2689-2>
- Pileczki, V., Cojocneanu-Petric, R., Maralani, M., Neagoe, I. B., & Sandulescu, R. (2016). MicroRNAs as regulators of apoptosis mechanisms in cancer. *Clujul Med*, *89*(1), 50-55. <https://doi.org/10.15386/cjmed-512>
- Purwanto, I., Heriyanto, D. S., Ghozali, A., Widodo, I., Dwiprahasto, I., Aryandono, T., & Haryana, S. M. (2020). Overexpression of programmed death-ligand 1 receptor mRNA as an independent negative prognostic factor for triple negative breast cancer. *World journal of oncology*, *11*(5), 216.
- Purwanto, I., Heriyanto, D. S., Widodo, I., Hakimi, M., Hardianti, M. S., Aryandono, T., & Haryana, S. M. (2021). MicroRNA-223 is associated with resistance towards platinum-based chemotherapy and worse prognosis in Indonesian triple-negative breast cancer patients. *Breast Cancer: Targets and Therapy*, 1-7.
- Qattan, A. (2020). Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease. *Int J Mol Sci*, *21*(23). <https://doi.org/10.3390/ijms21238905>
- Rafighdoust, Z., Baharara, J., Forghanifard, M. M., & Kerachian, M. A. (2021). Isolation and Characterization of Exosomes Derived From Breast Cancer MDA-MB-231 Cell Line [Research Article]. *Gene Cell Tissue*, *8*(1), e110505. <https://doi.org/10.5812/gct.110505>

- Riss, T. L., Moravec, R. A., Niles, A. L., Duellman, S., Benink, H. A., Worzella, T. J., & Minor, L. (2016). Cell viability assays. *Assay guidance manual [Internet]*.
- Shen, D. W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012). Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. *Pharmacol Rev*, *64*(3), 706-721. <https://doi.org/10.1124/pr.111.005637>
- Si, W., Shen, J., Zheng, H., & Fan, W. (2019). The role and mechanisms of action of microRNAs in cancer drug resistance. *Clinical Epigenetics*, *11*(1), 25. <https://doi.org/10.1186/s13148-018-0587-8>
- Szczepanek, J., Skorupa, M., & Tretyn, A. (2022). MicroRNA as a Potential Therapeutic Molecule in Cancer. *Cells*, *11*(6). <https://doi.org/10.3390/cells11061008>
- Tang, Y., Zhou, Y., & Li, H.-J. (2021). Advances in mesenchymal stem cell exosomes: a review. *Stem Cell Research & Therapy*, *12*(1), 71. <https://doi.org/10.1186/s13287-021-02138-7>
- Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022). Exosomes— nature’s lipid nanoparticles, a rising star in drug delivery and diagnostics. *ACS nano*, *16*(11), 17802-17846.
- Terrinoni, A., Calabrese, C., Basso, D., Aita, A., Caporali, S., Plebani, M., & Bernardini, S. (2019). The circulating miRNAs as diagnostic and prognostic markers. *Clinical Chemistry and Laboratory Medicine (CCLM)*, *57*(7), 932-953. <https://doi.org/doi:10.1515/cclm-2018-0838>
- Tokumar, Y., Asaoka, M., Oshi, M., Katsuta, E., Yan, L., Narayanan, S., Sugito, N., Matsushashi, N., Futamura, M., Akao, Y., Yoshida, K., & Takabe, K. (2020). High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. *International journal of molecular sciences*, *21*(9), 3213. <https://www.mdpi.com/1422-0067/21/9/3213>
- Tornillo, G., Knowlson, C., Kendrick, H., Cooke, J., Mirza, H., Aurrekoetxea-Rodríguez, I., Vivanco, M. D. M., Buckley, N. E., Grigoriadis, A., & Smalley, M. J. (2018). Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells. *Cell Rep*, *25*(13), 3674-3692.e3610. <https://doi.org/10.1016/j.celrep.2018.11.103>
- Villatoro, A. J., Martín-Astorga, M. D. C., Alcoholado, C., Sánchez-Martín, M. D. M., & Becerra, J. (2021). Proteomic Analysis of the Secretome and Exosomes of

- Feline Adipose-Derived Mesenchymal Stem Cells. *Animals (Basel)*, 11(2).
<https://doi.org/10.3390/ani11020295>
- Wang, L., He, J., Xu, H., Xu, L., & Li, N. (2016). MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer. *Am J Transl Res*, 8(6), 2716-2726.
- Wang, Q., Yao, J., Jin, Q., Wang, X., Zhu, H., Huang, F., Wang, W., Qiang, J., & Ni, Q. (2017). LAMP1 expression is associated with poor prognosis in breast cancer. *Oncol Lett*, 14(4), 4729-4735. <https://doi.org/10.3892/ol.2017.6757>
- Wang, R., Huang, Z., Qian, C., Wang, M., Zheng, Y., Jiang, R., & Yu, C. (2020). LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis. *Biochemical and Biophysical Research Communications*, 526(4), 1005-1012. <https://doi.org/https://doi.org/10.1016/j.bbrc.2020.01.170>
- Wang, Y., Zhang, Z., & Wang, J. (2018). MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1. *Oncology Reports*, 39(6), 2563-2574.
- Won, K. A., & Spruck, C. (2020). Triple-negative breast cancer therapy: Current and future perspectives. *International journal of oncology*, 57(6), 1245-1261.
- Wu, G., & Li, Y. (2022). TGF- β induced reprogramming and drug resistance in triple-negative breast cells. *BMC Pharmacology and Toxicology*, 23(1), 23. <https://doi.org/10.1186/s40360-022-00561-x>
- Wu, J., Sun, Z., Sun, H., & Li, Y. (2018). MicroRNA-27a promotes tumorigenesis via targeting AKT in triple negative breast cancer. *Molecular medicine reports*, 17(1), 562-570.
- Xia, C., Yang, Y., Kong, F., Kong, Q., & Shan, C. (2018). MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. *Biochimie*, 147, 98-104. <https://doi.org/https://doi.org/10.1016/j.biochi.2018.01.003>
- Xu, H., Qian, M., Zhao, B., Wu, C., Maskey, N., Song, H., Li, D., Song, J., Hua, K., & Fang, L. (2017). Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells. *Oncol Rep*, 37(3), 1619-1626. <https://doi.org/10.3892/or.2017.5404>
- Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J. M., Verschoor, S., Millar, E. K. A., van der Spek, P., Reis-Filho, J. S., Ramsay, R. G., O'Toole, S. A., McNeil, C. M., Sutherland, R. L., McKay, M. J., & Fox, S. B. (2011). Enhanced RAD21 cohesin expression confers poor prognosis and

- resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. *Breast Cancer Research*, 13(1), R9. <https://doi.org/10.1186/bcr2814>
- Xu, J., Li, X., Zhang, P., Luo, J., Mou, E., & Liu, S. (2022). miR-143-5p suppresses breast cancer progression by targeting the HIF-1 α -related GLUT1 pathway. *Oncology Letters*, 23(5), 147. <https://doi.org/10.3892/ol.2022.13268>
- Yang, Y. F., Lee, Y. C., Wang, Y. Y., Wang, C. H., Hou, M. F., & Yuan, S. F. (2019). YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells. *Kaohsiung J Med Sci*, 35(7), 408-416. <https://doi.org/10.1002/kjm2.12075>
- Yao, S., Yin, Y., Jin, G., Li, D., Li, M., Hu, Y., Feng, Y., Liu, Y., Bian, Z., Wang, X., Mao, Y., Zhang, J., Wu, Z., & Huang, Z. (2020). Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance. *Cancer Medicine*, 9(16), 5989-5998. <https://doi.org/https://doi.org/10.1002/cam4.3248>
- Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. *Frontiers in Molecular Biosciences*, 7, 193.
- Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-c. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*, 22(1), 61. <https://doi.org/10.1186/s13058-020-01296-5>
- Zare, M., Pemmada, R., Madhavan, M., Shailaja, A., Ramakrishna, S., Kandiyil, S. P., Donahue, J. M., & Thomas, V. (2022). Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. *Pharmaceutics*, 14(8). <https://doi.org/10.3390/pharmaceutics14081620>
- Zeng, Q. L., & Liu, D. W. (2021). Mesenchymal stem cell-derived exosomes: An emerging therapeutic strategy for normal and chronic wound healing. *World J Clin Cases*, 9(22), 6218-6233. <https://doi.org/10.12998/wjcc.v9.i22.6218>
- Zhang, H., Wu, J., Wu, J., Fan, Q., Zhou, J., Wu, J., Liu, S., Zang, J., Ye, J., Xiao, M., Tian, T., & Gao, J. (2019). Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice. *Journal of Nanobiotechnology*, 17(1), 29. <https://doi.org/10.1186/s12951-019-0461-7>
- Zhang, Q., Feng, Y., Liu, P., & Yang, J. (2017). MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. *Tumor Biology*, 39(7), 1010428317711312. <https://doi.org/10.1177/1010428317711312>
- Zhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020). Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted

Therapy Applications. *Int J Nanomedicine*, 15, 6917-6934.
<https://doi.org/10.2147/ijn.S264498>

Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., & Yang, C. (2022). Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. *Journal of Nanobiotechnology*, 20(1), 279.
<https://doi.org/10.1186/s12951-022-01472-z>

Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019). Exosomes: biogenesis, biologic function and clinical potential. *Cell & Bioscience*, 9(1), 19.
<https://doi.org/10.1186/s13578-019-0282-2>

Zhang, Y., Yang, W. K., Wen, G. M., Tang, H., Wu, C. A., Wu, Y. X., Jing, Z. L., Tang, M. S., Liu, G. L., Li, D. Z., Li, Y. H., & Deng, Y. J. (2019). High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival. *Mol Genet Genomic Med*, 7(11), e908. <https://doi.org/10.1002/mgg3.908>

Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021). Challenges and advances in clinical applications of mesenchymal stromal cells. *Journal of hematology & oncology*, 14(1), 24. <https://doi.org/10.1186/s13045-021-01037-x>